Joerg Wenzel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4667031/publications.pdf

Version: 2024-02-01

199 papers	8,922 citations	47 h-index	85 g-index
		47006	53230
216 all docs	216 docs citations	216 times ranked	9399 citing authors

#	Article	IF	Citations
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
2	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. Immunity, 2013, 39, 482-495.	14.3	338
3	Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. Journal of Allergy and Clinical Immunology, 2006, 118, 930-937.	2.9	335
4	Deconvolution of complex G proteinâ€“coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nature Biotechnology, 2010, 28, 943-949.	17.5	246
5	Loss-of-Function Mutations in the Keratin 5 Gene Lead to Dowling-Degos Disease. American Journal of Human Genetics, 2006, 78, 510-519.	6.2	238
6	IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. Journal of Allergy and Clinical Immunology, 2012, 129, 426-433.e8.	2.9	229
7	IL-36Î³ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions. Journal of Investigative Dermatology, 2015, 135, 1025-1032.	0.7	211
8	Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. Journal of Pathology, 2005, 205, 435-442.	4.5	202
9	An IFN-Associated Cytotoxic Cellular Immune Response against Viral, Self-, or Tumor Antigens Is a Common Pathogenetic Feature in â€œInterface Dermatitisâ€• Journal of Investigative Dermatology, 2008, 128, 2392-2402.	0.7	151
10	Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 720-727.	5.7	143
11	Mutations in POGLUT1, Encoding Protein O-Glucosyltransferase 1, Cause Autosomal-Dominant Dowling-Degos Disease. American Journal of Human Genetics, 2014, 94, 135-143.	6.2	136
12	Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. New England Journal of Medicine, 2014, 371, 2537-2538.	27.0	128
13	Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. British Journal of Dermatology, 2005, 153, 157-162.	1.5	123
14	The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. British Journal of Dermatology, 2007, 157, 752-757.	1.5	120
15	Cutaneous lupus erythematosus: new insights into pathogenesis andÂtherapeutic strategies. Nature Reviews Rheumatology, 2019, 15, 519-532.	8.0	119
16	Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. British Journal of Dermatology, 2005, 153, 1011-1015.	1.5	114
17	Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clinical and Experimental Dermatology, 2006, 31, 576-582.	1.3	113
18	Evidence for a Pathophysiological Role of Keratinocyte-Derived Type III Interferon (IFNÎ») in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2011, 131, 133-140.	0.7	110

#	Article	IF	Citations
19	Type I interferonâ€associated cytotoxic inflammation in lichen planus. Journal of Cutaneous Pathology, 2006, 33, 672-678.	1.3	107
20	Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. British Journal of Dermatology, 2005, 152, 258-264.	1.5	105
21	Role of granulocyte elastase and interleukin-6 in the diagnosis of male genital tract inflammation. Andrologia, 2005, 37, 188-194.	2.1	97
22	German guidelines for the diagnosis and therapy of localized scleroderma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 199-216.	0.8	97
23	Photosensitivity, Apoptosis, and Cytokines in the Pathogenesis of Lupus Erythematosus: a Critical Review. Clinical Reviews in Allergy and Immunology, 2014, 47, 148-162.	6.5	93
24	Type I Interferonâ€“Associated Recruitment of Cytotoxic Lymphocytes. American Journal of Clinical Pathology, 2005, 124, 37-48.	0.7	88
25	IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. Journal of Clinical Investigation, 2009, 119, 47-60.	8.2	84
26	Interleukin-36 in Infectious and Inflammatory Skin Diseases. Frontiers in Immunology, 2019, 10, 1162.	4.8	83
27	Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Experimental Dermatology, 2007, 16, 454-463.	2.9	73
28	Lipocalinâ€2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. British Journal of Dermatology, 2017, 177, 1385-1393.	1.5	73
29	Mutations in Î³-secretase subunitâ€“encoding PSENEN underlie Dowling-Degos disease associated with acne inversa. Journal of Clinical Investigation, 2017, 127, 1485-1490.	8.2	73
30	Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. Journal of Cutaneous Pathology, 2005, 32, 257-262.	1.3	71
31	Gene Expression Profiling of Lichen Planus Reflects CXCL9+-Mediated Inflammation and Distinguishes this Disease from Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2008, 128, 67-78.	0.7	68
32	JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. Journal of Investigative Dermatology, 2016, 136, 1281-1283.	0.7	68
33	Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. Experimental Dermatology, 2014, 23, 516-518.	2.9	67
34	Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective. Vaccines, 2021, 9, 944.	4.4	67
35	Genomeâ€wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Experimental Dermatology, 2015, 24, 510-515.	2.9	66
36	New reasons for histopathological nailâ€clipping examination in the diagnosis of onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 235-237.	2.4	64

#	Article	IF	Citations
37	Role of the Chemokine Receptor CCR4 and its Ligand Thymus- and Activation-Regulated Chemokine/CCL17 for Lymphocyte Recruitment in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2005, 124, 1241-1248.	0.7	63
38	Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Archives of Dermatological Research, 2009, 301, 83-86.	1.9	62
39	Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2017, 137, 1484-1492.	0.7	62
40	Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. Cancer Research, 2006, 66, 5427-5435.	0.9	59
41	Topical Treatment of Pyoderma gangraenosum. Dermatology, 2002, 205, 221-223.	2.1	55
42	Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica, 2010, 95, 1697-1704.	3.5	55
43	Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clinical and Experimental Dermatology, 2005, 30, 702-706.	1.3	54
44	Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. British Journal of Dermatology, 2010, 163, 197-200.	1.5	54
45	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. American Journal of Pathology, 2006, 169, 665-672.	3.8	53
46	Indoleamine 2,3-Dioxygenase (IDO). American Journal of Pathology, 2007, 171, 1936-1943.	3.8	52
47	Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidenceâ€based review of the literature. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1385-1391.	2.4	52
48	Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo. European Journal of Cell Biology, 2004, 83, 797-803.	3.6	48
49	Lupus erythematosus revisited. Seminars in Immunopathology, 2016, 38, 97-112.	6.1	48
50	Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. Journal of Investigative Dermatology, 2020, 140, 1451-1455.e13.	0.7	48
51	Keratitis-ichthyosis-deafness syndrome in association with follicular occlusion triad. European Journal of Dermatology, 2005, 15, 347-52.	0.6	46
52	Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus, 2010, 19, 1020-1028.	1.6	45
53	Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1165-1170.	2.4	43
54	A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Journal of Nanobiotechnology, 2016, 14, 57.	9.1	42

#	Article	IF	Citations
55	<scp>JAK</scp> inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Experimental Dermatology, 2017, 26, 728-730.	2.9	42
56	IP10/CXCL10 - CXCR3 Interaction: a Potential Self-recruiting Mechanism for Cytotoxic Lymphocytes in Lichen Sclerosus et Atrophicus. Acta Dermato-Venereologica, 2007, 87, 112-117.	1.3	41
57	Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Frontiers in Immunology, 2020, 11, 344.	4.8	41
58	CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. Journal of the American Academy of Dermatology, 2007, 56, 648-650.	1.2	40
59	Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin. Cancer Research, 2018, 78, 5917-5926.	0.9	40
60	The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Experimental Dermatology, 2005, 14, 454-459.	2.9	39
61	Real-Time Tissue Elastography as Promising Diagnostic Tool for Diagnosis of Lymph Node Metastases in Patients with Malignant Melanoma: A Prospective Single-Center Experience. Dermatology, 2013, 226, 81-90.	2.1	38
62	Successful Treatment of Chronic Discoid Lupus erythematosus of the Scalp with Imiquimod. Dermatology, 2002, 205, 416-418.	2.1	36
63	CXCR3 <-> ligandâ€“mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. Journal of the American Academy of Dermatology, 2008, 58, 437-442.	1.2	36
64	Interferon-Î± stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. British Journal of Dermatology, 2011, 165, 1118-1123.	1.5	36
65	Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. British Journal of Dermatology, 2004, 150, 1194-1197.	1.5	35
66	Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 1176-1179.	5.7	34
67	Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus, 2011, 20, 1300-1304.	1.6	34
68	Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clinical and Experimental Dermatology, 2012, 37, 139-142.	1.3	34
69	Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. British Journal of Dermatology, 2005, 153, 462-463.	1.5	33
70	The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. Journal of the American Academy of Dermatology, 2005, 53, 422-427.	1.2	33
71	P-Glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. Experimental Dermatology, 2011, 20, 450-452.	2.9	33
72	Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis. EMBO Journal, 2012, 31, 201-213.	7.8	33

#	Article	IF	Citations
73	Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. Experimental Dermatology, 2012, 21, 958-961.	2.9	32
74	High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus. Experimental Dermatology, 2018, 27, 95-97.	2.9	32
75	Exacerbation of subacute cutaneous lupus erythematosus following vaccination with <scp>BNT162b2 mRNA</scp> vaccine. Dermatologic Therapy, 2021, 34, e15017.	1.7	31
76	Kaposi's sarcoma of the gastrointestinal tract: Report of two cases and review of the literature. Pathology Research and Practice, 2007, 203, 227-231.	2.3	29
77	Role of High-Resolution Ultrasound and PET/CT Imaging for Preoperative Characterization of Sentinel Lymph Nodes in Cutaneous Melanoma. Ultrasound in Medicine and Biology, 2013, 39, 30-36.	1.5	29
78	Innate Immune-Response Mechanisms in Dermatomyositis: An Update on Pathogenesis, Diagnosis and Treatment. Drugs, 2014, 74, 981-998.	10.9	29
79	Antibodies targeting extractable nuclear antigens: historical development and current knowledge. British Journal of Dermatology, 2001, 145, 859-867.	1.5	28
80	Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. Journal of the American Academy of Dermatology, 2011, 64, 988-989.	1.2	28
81	Transcriptional profiling identifies an interferonâ€associated host immune response in invasive squamous cell carcinoma of the skin. International Journal of Cancer, 2008, 123, 2605-2615.	5.1	27
82	Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. Journal of Dermatological Science, 2018, 90, 68-74.	1.9	27
83	The Proinflammatory Cytokine IL-36Î³ Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues. Cell Reports, 2020, 33, 108515.	6.4	27
84	Indoleamine 2,3-dioxygenaseâ€“expressing antigen-presenting cells and peripheral T-cell tolerance. Journal of Allergy and Clinical Immunology, 2003, 112, 854-860.	2.9	26
85	Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. British Journal of Dermatology, 2006, 155, 861-862.	1.5	26
86	Spleen tyrosine kinase (<scp>SYK</scp>) is a potential target for the treatment of cutaneous lupus erythematosus patients. Experimental Dermatology, 2016, 25, 375-379.	2.9	26
87	Advances in the treatment of cutaneous lupus erythematosus. Lupus, 2016, 25, 830-837.	1.6	26
88	Real-time tissue elastography: AÂhelpful tool in the diagnosis of cutaneous melanoma?. Journal of the American Academy of Dermatology, 2011, 65, 424-426.	1.2	25
89	Increased expression of guanylate binding proteinâ€1 in lesional skin of patients with cutaneous lupus erythematosus. Experimental Dermatology, 2011, 20, 102-106.	2.9	25
90	Detection of IL-36Î³ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema. Journal of Allergy and Clinical Immunology, 2018, 142, 988-991.e4.	2.9	25

#	Article	IF	Citations
91	Treatment of Recalcitrant Dermatomyositis with Efalizumab. Acta Dermato-Venereologica, 2006, 86, 254-255.	1.3	24
92	Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. British Journal of Dermatology, 2010, 162, 870-874.	1.5	24
93	Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseasesâ€"Implications for Therapeutic Approaches. Cells, 2020, 9, 2627.	4.1	24
94	Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines. Dermatopathology (Basel, Switzerland), 2021, 8, 463-476.	1.5	24
95	Periodic genital pruritus caused by syringoma of the vulva. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 369-370.	2.8	23
96	Generalized Lichen Nitidus with Involvement of the Palms following Interferon Î± Treatment. Dermatology, 2007, 215, 236-239.	2.1	22
97	Successful Treatment of Dowlingâ€"Degos Disease with Er:YAG Laser. Dermatologic Surgery, 2002, 28, 748-750.	0.8	21
98	Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. British Journal of Dermatology, 2004, 150, 994-998.	1.5	21
99	Indoleamine 2,3-dioxygenaseâ€"expressing myeloid dendritic cells and macrophages in infectious and noninfectious cutaneous granulomas. Journal of the American Academy of Dermatology, 2011, 65, 819-832.	1.2	21
100	Clinical and Molecular Implications of MED15 in Head and Neck Squamous Cell Carcinoma. American Journal of Pathology, 2015, 185, 1114-1122.	3.8	21
101	Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2â€chlorodeoxyadenosine: case report and review of the literature. British Journal of Dermatology, 2017, 176, 481-487.	1.5	21
102	Autoantibodies in Patients with Lupus erythematosus: Spectrum and Frequencies. Dermatology, 2000, 201, 283-283.	2.1	20
103	Treatment of Dowling-Degos Disease With Er:YAG-Laser: Results After 2.5 Years. Dermatologic Surgery, 2003, 29, 1161-1162.	0.8	20
104	Expression of the autoantigen TRIM33/TIF1Î³ in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress. Clinical and Experimental Dermatology, 2017, 42, 659-662.	1.3	20
105	JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2021, 147, 2202-2212.e8.	2.9	20
106	Upcoming therapeutic targets in cutaneous lupus erythematous. Expert Review of Clinical Pharmacology, 2016, 9, 567-578.	3.1	19
107	Scleroderma and malignancy. Mechanisms of interrelationship. European Journal of Dermatology, 2002, 12, 296-300.	0.6	19
108	Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. British Journal of Dermatology, 2008, 159, 231-233.	1.5	18

#	Article	IF	Citations
109	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosusâ€"An Ongoing Need for International Consensus and Collaborations. Journal of Investigative Dermatology, 2019, 139, 270-276.	0.7	18
110	The value of lymphocytopenia as a marker of systemic involvement in cutaneous lupus erythematosus. British Journal of Dermatology, 2002, 146, 869-871.	1.5	17
111	Bacteremia Caused by a Novel Helicobacter Species in a 28-Year-Old Man with X-Linked Agammaglobulinemia. Journal of Clinical Microbiology, 2010, 48, 4672-4676.	3.9	17
112	Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Imaging, 2012, 39, 581-588.	6.4	16
113	Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (PrografTM). British Journal of Dermatology, 2004, 151, 927-928.	1.5	15
114	Efficacy of Ablative Laser Treatment in Galli-Galli Disease. Archives of Dermatology, 2011, 147, 317.	1.4	15
115	Altered Notch Signaling in Dowling-Degos Disease: Additional Mutations in POGLUT1 and Further Insights into Disease Pathogenesis. Journal of Investigative Dermatology, 2019, 139, 960-964.	0.7	15
116	Association of inclusion body myositis with subacute cutaneous lupus erythematosus. Rheumatology International, 2001, 21, 75-77.	3.0	14
117	Tryptase detection in bone-marrow blood: A new diagnostic tool in systemic mastocytosis. Journal of the American Academy of Dermatology, 2007, 56, 453-457.	1.2	14
118	High-Resolution Ultrasound Combined with Power Doppler Sonography Can Reduce the Number of Sentinel Lymph Node Biopsies in Cutaneous Melanoma. Dermatology, 2011, 222, 180-188.	2.1	14
119	Diagnostics of autoimmune bullous diseases in German dermatology departments. JDDG - Journal of the German Society of Dermatology, 2012, 10, 492-499.	0.8	14
120	Interleukin-36Î³ (IL-1F9) Identifies Psoriasis Among Patients With Erythroderma. Acta Dermato-Venereologica, 2016, 96, 386-387.	1.3	14
121	Nitrosative stress: a hallmark of the junctional inflammation in cutaneous lupus erythematosus. Clinical and Experimental Dermatology, 2013, 38, 96-97.	1.3	13
122	Candida induces the expression of <scp>IL</scp>â€36Î³ in human keratinocytes: implications for a pathogenâ€driven exacerbation of psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e403-e406.	2.4	13
123	Severity modeling of extreme insurance claims for tariffication. Insurance: Mathematics and Economics, 2019, 88, 77-92.	1.2	13
124	An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e49865.	2.5	13
125	Successful Rituximab Treatment of Severe Pemphigus Vulgaris Resistant to Multiple Immunosuppressants. Acta Dermato-Venereologica, 2005, -1, 1-1.	1.3	12
126	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. International Journal of Cancer, 2006, 118, 373-380.	5.1	12

#	Article	IF	Citations
127	Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clinical and Experimental Dermatology, 2008, 33, 347-348.	1.3	12
128	Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects. Handbook of Experimental Pharmacology, 2008, , 201-220.	1.8	12
129	Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma. Histology and Histopathology, 2011, 26, 997-1006.	0.7	12
130	Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib. Acta Dermato-Venereologica, 2020, 100, adv00144.	1.3	12
131	Deutsche Leitlinie zur Diagnostik und Therapie der zirkumskripten Sklerodermie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.8	11
132	Flame Figures in Urticarial Lesions Accompanying Systemic Lupus Erythematosus. American Journal of Dermatopathology, 2001, 23, 533-535.	0.6	10
133	Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus. Frontiers in Medicine, 0, 9, .	2.6	10
134	FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate. Scandinavian Journal of Rheumatology, 2002, 31, 216-220.	1.1	9
135	More on Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. New England Journal of Medicine, 2015, 372, 1273-1274.	27.0	9
136	The role of histological presentation in erythroderma. International Journal of Dermatology, 2017, 56, 400-404.	1.0	9
137	Annular plaques mimicking Rowellâ€™s syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon?. Journal of Dermatology, 2022, 49, 151-156.	1.2	9
138	Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A doubleâ€blind Phase Ib study. Experimental Dermatology, 2021, 30, 1686-1692.	2.9	9
139	Granuloma Annulare Induced by Scabies. Acta Dermato-Venereologica, 2003, 83, 318-318.	1.3	8
140	Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature. Dermatologic Surgery, 2011, 37, 1684-1688.	0.8	8
141	Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1316-1325.	6.4	8
142	Applications of the central limit theorem for pricing Cliquet-style options. European Actuarial Journal, 2017, 7, 465-480.	1.1	8
143	Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. Journal of Dermatology, 2020, 47, 397-401.	1.2	8
144	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus â€“ PartÂ1: Classification, diagnosis, prevention, activity scores. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1236-1247.	0.8	8

#	Article	IF	Citations
145	Epigallocatechinâ€3â€gallate exhibits antiâ€inflammatory effects in a human interface dermatitis modelâ€”implications for therapy. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 144-153.	2.4	8
146	Immunostimulatory Endogenous Nucleic Acids Perpetuate Interface Dermatitisâ€”Translation of Pathogenic Fundamentals Into an In Vitro Model. Frontiers in Immunology, 2020, 11, 622511.	4.8	8
147	Presence of antinuclear antibodies in patients with lupus erythematosus is correlated with diminished Tâ€helper cells. British Journal of Dermatology, 2000, 143, 1100-1101.	1.5	7
148	A novelKRT86mutation in a Turkish family with monilethrix, and identification of maternal mosaicism. Clinical and Experimental Dermatology, 2015, 40, 781-785.	1.3	7
149	Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Multiple Sclerosis Journal, 2018, 24, 1785-1787.	3.0	6
150	FRI0193â€…2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
151	Cutaneous lupus erythematosus: The impact of selfâ€amplifying innate and adaptive immune responses and future prospects of targeted therapies. Experimental Dermatology, 2020, 29, 1123-1132.	2.9	6
152	NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus. Experimental Dermatology, 2021, 30, 847-852.	2.9	6
153	Targeted Therapies in Autoimmune Skin Diseases. Journal of Investigative Dermatology, 2022, 142, 969-975.e7.	0.7	6
154	Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patientsâ€”Focus on Clinical and Histopathological Variation. Dermatopathology (Basel, Switzerland), 2022, 9, 60-81.	1.5	6
155	Infraorbital eyelid edema as the presenting sign of bronchogenic carcinoma. International Journal of Dermatology, 2002, 41, 386-387.	1.0	5
156	Treatment of Dowling-Degos Disease With Er. Dermatologic Surgery, 2003, 29, 1161-1162.	0.8	5
157	Lupus tumidus following the lines of Blaschko. International Journal of Dermatology, 2013, 52, 1615-1617.	1.0	5
158	A wideband single-PLL RF receiver for simultaneous multi-band and multi-channel digital car Radio reception. , 2016, , .		5
159	EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress. Journal of Oncology, 2019, 2019, 1-13.	1.3	5
160	Anti-cardiolipin antibodies in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 162-163.	5.7	4
161	Letter to the Editor. Lupus, 2005, 14, 569-569.	1.6	4
162	Real time tissue elastography for diagnosis of cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 713-715.	1.3	4

#	Article	IF	Citations
163	Resistance to water and abrasion of a broad-spectrum sunscreen: a prospective, open-label study. Experimental Dermatology, 2016, 25, 151-152.	2.9	4
164	Bullous lupus erythematosus in a patient with pre-existing dermatomyositis. Rheumatology International, 2004, 24, 114-116.	3.0	3
165	A Rapidly Growing Squamous Cell Carcinoma or Keratoacanthoma or Both?. Acta Dermato-Venereologica, 2007, 87, 447-448.	1.3	3
166	Indoleamine 2,3â€dioxygenase expression in early keratocyte neoplasia of the lower lip correlates to the degree of cell atypia. Pathology International, 2012, 62, 105-111.	1.3	3
167	Tumour necrosis factor-Î±-inhibitor-induced neutrophilic folliculitis presenting with strong lesional expression of interleukin-36Î³. Clinical and Experimental Dermatology, 2018, 43, 458-459.	1.3	3
168	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus â€“ Part 2: Therapy, risk factors and other special topics. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1371-1395.	0.8	3
169	Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiency. IScience, 2021, 24, 102833.	4.1	3
170	Fluorescence-Activated Cell Sorter Analysis in Patients With Cutaneous Lupus Erythematosus. Archives of Dermatology, 1999, 135, 720-721.	1.4	3
171	Type I Interferon-Associated Recruitment of Cytotoxic Lymphocytes. American Journal of Clinical Pathology, 2005, 124, 37-48.	0.7	3
172	Answer to the letter of Brockow et al. concerning our article â€˜Safety of rush insect venom immunotherapy. Results of a retrospective study in 178 patientsâ€™. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 127-127.	5.7	2
173	Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris. Dermatologic Therapy, 2014, 27, 55-59.	1.7	2
174	Unusual flaccid blistering with mucosal involvement upon immune checkpoint inhibition. JDDG - Journal of the German Society of Dermatology, 2020, 18, 149-152.	0.8	2
175	Vitiligoâ€like depigmentation subsequent to subacute cutaneous lupus erythematosus and hydroxychloroquine treatment. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1470-1473.	0.8	2
176	Travelâ€associated infectious skin diseases. JDDG - Journal of the German Society of Dermatology, 2020, 18, 730-733.	0.8	2
177	Grzybowskiâ€™s Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Diseaseâ€”An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report. Dermatology and Therapy, 2021, 11, 625-638.	3.0	2
178	S2kâ€Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes â€“ Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1371-1395.	0.8	2
179	Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	2
180	Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin. Dermatology, 2007, 215, 81-83.	2.1	1

#	Article	IF	Citations
181	Phymatous Transformation of Facial Cutaneous Vascular Malformations: Clues to Phyma Pathogenesis. JAMA Dermatology, 2013, 149, 368.	4.1	1
182	APRIL expression is upregulated in atopic dermatitis skin lesions and at sites of antigen driven allergic skin inflammation in mice. Clinical Immunology, 2020, 219, 108556.	3.2	1
183	Cutaneous leishmaniasis with multiple ulcerated lesions in an immunocompetent patient caused by Leishmania major. JDDG - Journal of the German Society of Dermatology, 2020, 18, 625-627.	0.8	1
184	Efficacy and safety of treatment for Old World cutaneous leishmaniasis in pediatric patients: a case series. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1067-1073.	0.8	1
185	Biomarkers for psoriasis skin lesions. Italian Journal of Dermatology and Venereology, 2017, 152, 441-446.	0.2	1
186	Osteoma Cutis and Calcinosis Cutis: "Similar but Different". Journal of Clinical and Aesthetic Dermatology, 2020, 13, 28-31.	0.1	1
187	Discoid and subacute cutaneous lupus erythematosus: detection of differences in peripheral lymphocyte numbers. Acta Dermato-Venereologica, 2000, 80, 456.	1.3	1
188	JAK1/2 inhibitor but not ILâ€4 receptor alpha antibody suppresses allergenâ€mediated activation of human basophils in vitro. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2253-2256.	5.7	1
189	Ultrasound detection ofÂaÂPET/CT negative lymph node metastasis inÂcutaneous melanoma. European Journal of Dermatology, 2010, 20, 835-6.	0.6	1
190	PS1-030. Tyrosine kinase inhibitor SU6668 blocks the polyIC-induced IFNÎ»-expression of keratinocytes: TBK1 as a potential drug-target for the treatment of cutaneous lupus erythematosus. Cytokine, 2011, 56, 24.	3.2	0
191	Acknowledging the Clinical Heterogeneity of Lupus Erythematosus. , 2015, , 121-134.		0
192	Lokalisierte Pityriasis rubra pilaris in der Schwangerschaft: Eine sehr seltene Sonderform mit therapeutischer Herausforderung. JDDG - Journal of the German Society of Dermatology, 2019, 17, 28-30.	0.8	0
193	FRI0192â€…A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
194	Therapyâ€resistant erythema of the rima ani. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1518-1521.	0.8	0
195	Interferonâ€beta as an enhancer of paraviral exanthema during influenza virus infection. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e228-e230.	2.4	0
196	Pyogenic granuloma-like lesion: a wolf in sheep's clothing. European Journal of Dermatology, 2011, 21, 121-122.	0.6	0
197	EntzÃ¼ndliche Dermatosen mit Interface-Dermatitis. , 2015, , 1-37.		0
198	EntzÃ¼ndliche Dermatosen mit Interface-Dermatitis. , 2016, , 127-151.		0

#	Article	IF	Citations
199	The Initial Stage of Neutrophilic Dermatosis of the Dorsal Hands: A Case Report and Discussion of Differential Diagnoses. Journal of Clinical and Aesthetic Dermatology, 2021, 14, 26-28.	0.1	0